Generating AI summary…

Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

SHANGHAI, Aug 17 (Reuters) - Swiss generic drugmaker Sandoz will pay up to $77 million upfront to Shanghai Henlius Biotech for rights to three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday. The three treatments are in clinical or pre-clinical development. Biosimilars are similar versions of biologic drugs and are comparable to generic continue reading...